University of Valencia logo Logo Scientific Technological Offer Logo del portal

Description

The Molecular Oncology group is strongly involved in translational research in cancer with special interest in the search for biomarkers related to angiogenesis, immunoregulation and tumour stem cells in cancer, characterised by its multidisciplinary nature. The team includes researchers with expertise in different areas such as: molecular and cell biologists, clinical oncologists, thoracic surgeons, pulmonologists, pathologists and immunologists.

The group's research activity is linked to the General University Hospital of Valencia, a tertiary reference hospital in Valencia, and is closely associated with the activity of three important specialised departments: Medical Oncology (about 648,000 inhabitants), Thoracic Surgery (760,000 inhabitants) and Functional Breast Unit (648,000 inhabitants). They are also very active in recruiting patients for clinical trials.

The main lines of translational research of the group are:

1) Molecular markers in lung, colorectal, melanoma and breast cancer, mainly focused on early diagnosis and the search for prognostic and predictive factors of response to treatment through different omics approaches (genomics, transcriptomics, metabolomics).
2) Liquid biopsy: for the analysis of markers in minimally invasive samples.
3) Angiogenesis and immunoregulation. Study possible interrelationships between tumour neovascularisation, the presence of immunoregulatory cell populations (Tregs cells, myelosuppressive cells, dendritic cells) and tumour recurrence or progression.
4) Tumour stem cells (CSC): characterisation and isolation of CSCs from lung cancer patient samples. Development of in vitro and in vivo models for the design of new therapeutic strategies for CSC population control.

Goals CT
  • Validate minimally invasive biomarkers that allow the selection of individuals most likely to develop lung cancer.
  • Develop in vitro and in vivo models from human CSCs (obtained from patients) to test new therapeutic strategies.
  • Research into tumour immunology in order to find new therapeutic targets.
  • Integrate knowledge derived from the study of the tumour microenvironment in order to develop new prognostic and predictive biomarkers.
Research lines
  • Molecular markers in oncology

    Diagnostic, prognostic and/or predictive biomarkers: in lung cancer, head and neck cancer, colon cancer, breast cancer, melanoma, among others, through different omics approaches (genomics, transcriptomics, metabolomics).

  • Tumour Stem Cell (CSC)

    Characterisation and isolation of CSCs from tumour samples. Development of in vitro and in vivo models for the design of new therapeutic strategies to control the CSC population.

  • Liquid biopsy

    Analysis of biomarkers in minimally invasive samples (saliva, blood, cerebrospinal fluid, pleural fluid, etc.), with the aim of improving diagnosis, personalising treatments and monitoring patients more closely (detection of resistance and relapses).

  • Angiogenesis and immunoregulation

    Study of interrelationships between tumour neovascularisation, the presence of immunoregulatory cell populations and recurrence or progression in the tumour microenvironment.

Management
  • CAMPS HERRERO, CARLOS
  • PDI-Catedratic/a d'Universitat
View details
Members
  • CALABUIG FARIÑAS, SILVIA
  • PDI-Prof. Permanent Laboral Ppl
View details
  • GUIJARRO JORGE, RICARDO
  • PDI-Catedratic/a d'Universitat
View details
Non-UV research staff

Contributors

  • Francisco de Asís Aparisi Aparisi - Consortium of the General University Hospital of Valencia
  • Ana Blasco Cordellat - Consortium of the General University Hospital of Valencia
  • Cristina Caballero Díaz - Consortium of the General University Hospital of Valencia
  • Elena Duréndez Sáez - Research Foundation of the General University Hospital of Valencia
  • Eva Escorihuela Alares - Research Foundation of the General University Hospital of Valencia
  • Sandra Gallach García - Research Foundation of the General University Hospital of Valencia
  • Mireia Gil Raga - Hospital de Requena (Valencia)
  • Alejandro Herreros Pomares - Research Foundation of the General University Hospital of Valencia
  • Vega Iranzo González-Cruz - Consortium of the General University Hospital of Valencia
  • Eloisa Jantus Lewintre - Research Foundation of the General University Hospital of Valencia
  • Marais Mosqueda Frometa - Research Foundation of the General University Hospital of Valencia
  • María José Safont Aguilera - Consortium of the General University Hospital of Valencia
  • Rafael Sirera Pérez - Universitat Politècnica de València

Work group

  • Cristóbal Aguilar Gallardo - Research Foundation of the General University Hospital of Valencia
Scientific production by UV researcher
  • GUIJARRO JORGE, RICARDO
    PDI-Catedratic/a d'Universitat
    Expandir
Associated structure
Contact group details
Molecular Oncology (OncoMol)

Blasco Ibáñez Campus

Av. Blasco Ibáñez, 15

46010 València (Valencia)

+34 963 983 372

Geolocation

fihgu.general-valencia.san.gva.es

carlos.camps@uv.es

Contact people
  • CAMPS HERRERO, CARLOS
  • PDI-Catedratic/a d'Universitat
View details